In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to
streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations,
it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of
technology in healthcare.
Enhanced Radiology Workflows
Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as
PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical
images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology
departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not
overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.
Errors of any kind in medical settings can have dire consequences for patients and healthcare systems. Unfortunately, negligence, misdiagnosis, and
medication errors aren't uncommon in the UK.
In this article, we discuss the nature of medication errors in the NHS, outline potential causes, and delve into how and why technology could be turning the tide
on the issue.
Prevalence and consequences of medication errors
Medication errors are incidents involved with the administering, prescribing, dispensing or monitoring of medicine to patients. It can happen at many different
steps in the healthcare process and by any medical professional in the system. Many cases are avoidable.
According to analysis from BMJ, there are an estimated 237 million medication errors made in England every year. The majority of these are minor errors, but 1 in 4
cases has the potential to cause moderate to serious harm to patients.
Not only do these errors cost the NHS significantly, at almost £100 million every year, but there is a shocking cost to public health. Lives are being lost because
of medication errors which is unforgivable and tragic for the families involved.
Drains on NHS resources have widespread impacts on public health and the operations of healthcare organisations up and down the country. Individual errors and
mistakes may seem inconsequential (in minor cases), but they all add up in the big picture to a significant concern for policymakers.
Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations.
Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain.
The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling
machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care.
It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients.
In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.
Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy
software supplier Cegedim Rx.
The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said.
Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5).
Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his
leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community
pharmacy."
Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on
both care delivery and technology implementation.
Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva.
"An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and
Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain
regulatory approval in the UK."
In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology.
Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."
A recent report by the Company Chemists' Association (CCA) has revealed a significant disparity in patient engagement with the Pharmacy First service across
the UK.
In response, Santosh Sahu, Founder and CEO at Charac, has emphasised the need for technological reform to address "the interoperability gap between pharmacists
and GPs".
Sahu identified the lack of GP referrals for Pharmacy First consultations as a key issue, attributing it to inadequate IT infrastructure.
He urged the sector to "implement technological reforms to enhance interoperability between pharmacists and GPs, enabling them to share patient records, identify
care pathways, and address health needs more effectively".
The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK.
Through this funding, the government aims to create the most advanced genomic healthcare system in the world.
"Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a
£175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC.
The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA.
"£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using
whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC.
"An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing
technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information
such as routine scans.
Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU
Commission proposal. An agreement, in principle, has been reached by the UK and EU.
The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure
that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom.
Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for
Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result.
However, the burden on the UK Pharma supply chain will be eased.
Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023
Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on
the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products
within the Northern Ireland market.
Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The
pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee
the supply of medicines within the whole United Kingdom.
A massive global technology outage on Friday has disrupted essential services, including healthcare, airlines, banks, and broadcasters worldwide.
The outage, attributed to a flawed update from cybersecurity firm CrowdStrike, has also affected the National Health Service (NHS) in the UK, with several hospitals
and GP practices losing access to their computer systems.
Community pharmacies are also facing significant disruptions. Services such as accessing prescriptions from GPs and medicine deliveries have been affected, causing
inconvenience to patients and healthcare providers.
An NHS spokesperson said: "The NHS is aware of a global IT outage and an issue with EMIS, an appointment and patient record system, which is causing disruption in
the majority of GP practices."
The spokesperson assured that the NHS has long-standing measures in place to manage such disruptions, including the use of paper patient records and handwritten
prescriptions, and the usual phone systems to contact GPs.
The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll.
This trend appears to be persisting with the study showing a generally favourable view of the sector.
The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series
that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians.
The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe
and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field.
Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic
levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.
American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division.
Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division.
He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into
UK community pharmacies.
As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small
multiple operators) can be fully understood and supported.
The new 'How to Involve and Engage Patients on Digital Health Tech Innovation' learning module has been created specifically to support the development and
delivery of patient-centric technologies, at a time of critical digital transformation in the NHS.
The foundation level module will be freely available at www.orcha-digitalhealthacademy.com and on the Health Education England NHS Learning Hub (learninghub.nhs.uk).
No training previously exists on conducting effective patient and public involvement and engagement (PPIE), leading to wasted resource on unsuitable technologies
at a time when the healthcare system simply cannot afford it. The module aims to educate innovators who are creating new technology, and the clinicians who are
prescribing these solutions. Crucially, the module also provides valuable support to the 500 NHS clinicians who are on the Clinical Entrepreneur Programme.
The module is an introduction to the first evidence-based framework for PPIE, launched by the University of Plymouth, the AHSN Network (the national voice of the
15 academic health science networks in England) and Boehringer Ingelheim UK & Ireland. It helps to fast-track learning for the EnACT principles described in the
framework, outlining how to involve patients in product innovation and critical issues such as data privacy, intellectual property, inclusivity, reimbursement,
useability, and recruitment of patients.
Rowlands Pharmacy has joined hands with healthcare software company HasHealth for an enhanced digital proposition to facilitate seamless delivery of a raft of
clinical services including flu and travel vaccinations.
The new system is now available across 400 Rowlands pharmacies across the UK.
The partnership comes as Rowlands Pharmacy strives to provide patients with a seamless booking experience whilst minimising time-consuming administration for pharmacy
staff, with its waiting list, medical pre-screen questionnaires and resource management capabilities, the company said in a statement.
HasHealth offers a virtual healthcare software solution that allows community pharmacies to schedule, manage, and communicate with patients easily online. It combines
its cutting-edge video technology with booking and management software, which can be adapted to any clinical service.
Nigel Swift, managing director at Rowlands Pharmacy, commented: "We pride ourselves on listening to our staff, based on feedback we knew we could do better with our
digital proposition for clinical services and flu vaccinations in particular.
he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair.
Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of
Medicine and Health Sciences, responsible for developing the clinical teaching at Keele.
Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education,
particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a
principal fellowship of the Higher Education Academy in November 2020.
Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of
retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.
The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president.
"As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities.
These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and
inequalities," said ABPI in a statement.
At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients.
She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.
Following centuries of stigma, the importance of mental wellness is finally matching that of physical healthcare.
Conditions such as depression have become common topics in the media, particularly in the last few years as celebrities and experts warned against the pressures of
social media. The bouts of isolation connected with the Covid-19 pandemic exacerbated the issue, with the British Medical Association declaring a UK mental health
crisis at the end of 2022.
This media attention has led to acknowledgement of the realities of mental health problems from the government and medical sector, and a recognition that these
need to be approached differently to physical ailments when it comes to providing treatment.
If you are motivated to be involved in this rapidly changing industry, consider these rewarding business ideas for developing a career in mental health.
Become a counsellor
Counselling is a broad term, but essentially it is the practice of having impartial conversation with patients about their life experiences with a view to overcoming
emotional obstacles and trauma. Training can take three to five years depending on whether you are getting a degree or diploma, and there are many opportunities to
specialise both during and after your education.
Psychotherapy is a similar field, but this is a more academically focused course that tends to be concerned with long-term or particularly complex mental health
issues. You will need a post-graduate qualification and several years of training to become certified.
ITV on Tuesday (Aug 15) said it had agreed to invest in pain relief brand Flarin Holdings Ltd, making it the British broadcaster's first consumer healthcare
investment.
The company has agreed to subscribe for £2 million worth of shares in Flarin, with an option to subscribe for two more tranches of 1.5 million pounds each.
In return, Flarin would get advertising space across ITV's channels and ITVX.
ITV said its investment will "help Flarin build mass market brand awareness by bringing the brand to millions of consumers via ITV platforms. This will be a step
change in the size of the campaign and the approach to scaling the Flarin brand to date."
Director of ITV AdVentures, Sheena Amin, said: "It's fantastic to be announcing our latest Media for Equity investment into Flarin. With its innovative and
patented lipid technology, Flarin offers many unique benefits to those suffering from joint and muscular pain compared to any other product on the market.
Flarin is already one of the fastest growing analgesics in the market and I am confident that we will see the company grow to new heights following a brand
building campaign across ITV."
Positive Solutions is set to launch its new, innovative, cloud-based medicines management system - HxCare which will be showcased in October at the Care Show.
HxCare will be free of charge to community pharmacies signing up to the HxCare Affiliate Programme (HxCAP) making it an ideal platform to support existing care home
business and attract new ones.
The cloud-based medicines management system aims to digitise workflows, reduce errors and free up care providers to spend more time delivering care to their residents.
Designed to be truly mobile, HxCare will be tablet based and has been developed by working closely with both care homes across the sector and their pharmacy partners
who relish the prospect of an eMAR solution that integrates into their Analyst PMR.
It is one of five new products being launched by Positive Solutions on the Hx platform this year.
HxConsult is already live supporting pharmacies looking to maximise their service revenue. HxIntel will deliver real-time dashboards, reports and insights into the
performance of pharmacy businesses of all sizes. My Health Hub will revolutionise patient pharmacy relationships whilst HxDispense is set to be the ultimate next
generation PMR system. This modular, cloud-based interoperable ecosystem takes healthcare technology to a new level.
The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation.
Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new
prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and
help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships.
Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium
(IRDiRC) Task Force on Drug Repurposing Guidebook.
Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma
industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.